Stangl R, Altendorf-Hofmann A, Charnley R M, Scheele J
Chirurgische Klinik mit Poliklinik, Universität Erlangen-Nürnberg, Germany.
Lancet. 1994 Jun 4;343(8910):1405-10. doi: 10.1016/s0140-6736(94)92529-1.
Palliative treatment of unresectable colorectal liver metastases is common and often justified with reference to historical data on the natural history of the disease. However, in view of the improved diagnostic accuracy of modern imaging techniques, these previously published series do not provide sufficient guidance to judge the prognostic efficacy of palliative treatment. In the late 1970s we started prospectively to collect data on consecutive patients with colorectal liver metastases according to a standard protocol. We now present data derived from this series on factors that may affect outcome in untreated patients. Between January, 1980, and December, 1990, 1099 consecutive patients were recorded, of whom 566 (51.5%) received no treatment for their hepatic tumour. Excluding 34 early deaths and 48 patients with a second malignant tumour, 484 patients provided the basis for analysis. All patients were followed up to July 1, 1993, or death. At the closing date of the study only 1 untreated patient was still alive. The impact of various factors on survival was analysed by univariate and multivariate analyses. Six independent determinants of survival were identified in the following order: percentage liver volume replaced by tumour (LVRT), grade of malignancy of the primary tumour, presence of extrahepatic disease, mesenteric lymph-node involvement, serum carcino-embryonic antigen, and age. The subsequent combination of the independently significant factors, separately for patients with up to or more than 25% LVRT, yielded a prognostic tree that displayed median survival times of various subgroups of 3.8 to 21.3 months. These findings provide a framework to estimate the survival expectancy of untreated patients, thereby allowing improved assessment of the prognostic significance of palliative therapeutic approaches.
不可切除的结直肠癌肝转移的姑息治疗很常见,并且常常依据该病自然史的历史数据而被证明是合理的。然而,鉴于现代成像技术诊断准确性的提高,这些先前发表的系列研究并不能为判断姑息治疗的预后疗效提供足够的指导。在20世纪70年代后期,我们开始按照标准方案前瞻性地收集连续性结直肠癌肝转移患者的数据。我们现在呈现来自该系列研究的关于可能影响未治疗患者预后的因素的数据。在1980年1月至1990年12月期间,记录了1099例连续性患者,其中566例(51.5%)未对其肝肿瘤进行治疗。排除34例早期死亡患者和48例患有第二种恶性肿瘤的患者后,484例患者成为分析的基础。所有患者均随访至1993年7月1日或死亡。在研究截止日期时,仅有1例未治疗患者仍存活。通过单因素和多因素分析来分析各种因素对生存的影响。按以下顺序确定了六个独立的生存决定因素:肿瘤取代肝脏体积的百分比(LVRT)、原发肿瘤的恶性程度、肝外疾病的存在、肠系膜淋巴结受累情况、血清癌胚抗原以及年龄。随后分别针对LVRT高达或超过25%的患者,将独立显著的因素进行组合,得出了一个预后树,该预后树显示了各个亚组的中位生存时间为3.8至21.3个月。这些发现提供了一个框架来估计未治疗患者的预期生存期,从而能够更好地评估姑息治疗方法的预后意义。